Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postmenopausal Osteoporosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

NCT00540878
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (400 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

NCT00709540
View directory record Official record
Conditions
Osteoporosis
Interventions
ACE-011 or placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin K and Bone Turnover in Postmenopausal Women

NCT00062595
View directory record Official record
Conditions
Osteoporosis
Interventions
phylloquinone (K1), menatetranone (MK4)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2008 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hesperidin and Bone Health in Postmenopausal Women

NCT01881204
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Hesperidin and Calcilock, Hesperidin, Control
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
150 mg, 75 mg, 100 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00504166
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
alendronate sodium, placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

NCT03710889
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk, Osteoporosis Fracture, Osteoporosis Localized to Spine, Osteoporosis, Age-Related, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Golden, Colorado • Gainesville, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parameters of Exercise to Prevent Osteoporosis

NCT04063813
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Experimental: 40 minute up trial, Experimental: 40 minute down trial, Experimental: Two 20 minute up trials, Experimental: Two 20 min down trials, Active Comparator: Sedentary trial
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional

An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass

NCT00078026
View directory record Official record
Conditions
Osteoporosis
Interventions
Apomine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Omaha, Nebraska • West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

NCT04431960
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
Interventions
blackcurrant (BC) extract
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

NCT00587925
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
Bone Mineral Density
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT03227458
View directory record Official record
Conditions
Low Bone Mass, Osteoporosis, Postmenopausal
Interventions
DHEA, Placebo, Exercise
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 4 Interventional

Romosozumab Use to Build Skeletal Integrity

NCT05058976
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions
Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

NCT01928082
View directory record Official record
Conditions
Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
Interventions
Transdermal estradiol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

NCT00118508
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Blueberries on Bone Turnover

NCT02630797
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions
Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 21, 2026, 2:19 PM EDT